Solid Biosciences (SLDB) Net Equity Issued and Repurchased (2017 - 2024)

Solid Biosciences has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $6.9 million in Q4 2024.

• Quarterly Net Equity Issued and Repurchased rose 1486.21% year-over-year to $6.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $18.5 million (up 522.06% YoY) and the FY2025 annual result came in at $6.8 million, down 63.04% from the prior year.
• Net Equity Issued and Repurchased grew to $6.9 million in Q4 2024 per SLDB's latest filing, from $3.1 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $134.9 million in Q1 2021 and troughed at $435000.0 in Q4 2023.
• A 3-year average of $22.3 million and a median of $3.1 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 1486.21% in 2024, down 112.68% in 2024.
• Over 3 years, Net Equity Issued and Repurchased stood at $134.9 million in 2021, then sank by 99.68% to $435000.0 in 2023, then soared by 1486.21% to $6.9 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $6.9 million, $3.1 million, and $5.4 million for Q4 2024, Q3 2024, and Q2 2024 respectively.